Argenx Shares Slide After Vyvgart Myositis Trial Strategy Shift
Argenx shares fell 5.7% in Brussels trading after the company updated its late-stage trial plan for Vyvgart in myositis. Management said it will stop pursuing one myositis subtype in the program and will analyze the two remaining subgroups independently, citing less robust evidence of efficacy in one subgroup. J.P. Morgan noted concerns over the DM…